Press/Media
- 225 - 250 out of 891 results
Search results
-
OSU-CHS EARNS NO. 6 RANKING FOR GRADS PRACTICING IN HPSAS
Stephens, J. & Blankenship, D.
25/07/24
1 item of Media coverage
Press/Media
-
OSU-CHS EARNS NO. 6 RANKING FOR GRADS PRACTICING IN HPSAS
Stephens, J. & Blankenship, D.
25/07/24
1 item of Media coverage
Press/Media
-
-
-
-
Investigators at Oklahoma State University Detail Findings in Chronic Obstructive Pulmonary Disease (The Current State of Health Inequities In Copd)
1/07/24
1 item of Media coverage
Press/Media
-
Monthly: Collegium Pharmaceutical (COLL: $32.20) decreases 3% on robust volume in June 2024
1/07/24
1 item of Media coverage
Press/Media
-
Q2/2024: Monthly: Biohaven Pharmaceutical Holding (BHVN: $34.71) in bottom 3% performers of NYSE market in past quarter
1/07/24
1 item of Media coverage
Press/Media
-
OSU-CHS names Coffey chair of psychiatry and behavioral sciences department
29/06/24
1 item of Media coverage
Press/Media
-
OSU-CHS Names Coffey Chair of Psychiatry and Behavioral Sciences Department
28/06/24 → 29/06/24
2 items of Media coverage
Press/Media
-
-
OSU-CHS NAMES COFFEY CHAIR OF PSYCHIATRY AND BEHAVIORAL SCIENCES DEPARTMENT
28/06/24
1 item of Media coverage
Press/Media
-
Monthly: Collegium Pharmaceutical (COLL: $32.20) decreases 3% on robust volume in June 2024
28/06/24
1 item of Media coverage
Press/Media
-
Q2/2024: Monthly: Biohaven Pharmaceutical Holding (BHVN: $34.71) in bottom 3% performers of NYSE market in past quarter
28/06/24
1 item of Media coverage
Press/Media
-
-
OSU/A&M Regents approve personnel actions
David, C., Kaul, A., Murray, K., Guevara, C., Spencer, H., Delen, D., Cole, A. & Ford, B.
14/06/24
1 item of Media coverage
Press/Media
-
Collegium Pharmaceutical increases 3.8% in 2024, but lagging Medical/Drugs sector
14/06/24
1 item of Media coverage
Press/Media
-
OSU/A&M REGENTS APPROVE PERSONNEL ACTIONSNEW APPOINTMENTSCHANGES IN APPOINTMENT
David, C., Kaul, A., Murray, K., Guevara, C., Spencer, H., Delen, D., Cole, A. & Ford, B.
14/06/24
1 item of Media coverage
Press/Media
-
Research from Oklahoma State University Center for Health Sciences in the Area of Drug Development Described (Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials)
Vassar, M., Hughes, G. & Nowlin, W.
11/06/24
1 item of Media coverage
Press/Media
-
Monthly: Biohaven Pharmaceutical Holding (BHVN: $35.10) drops 10% on high volatility in May 2024
31/05/24
1 item of Media coverage
Press/Media
-
Mental health concerns are 365day problem for many Oklahomans
19/05/24
1 item of Media coverage
Press/Media
-
-
This Oklahoma medical school is trying to turn the tide on Native, rural doctor shortage
18/05/24
1 item of Media coverage
Press/Media